For research use only. Not for therapeutic Use.
CB-5339 is an oral activity potent p97 inhibitor with an IC50 <30 nM. CB-5339 can be used for leukemia research[1]. CB-5339 extracted from WO2015109285A1 compound FF07.
CB-5339( 0-1.6 μM; 24-48 hours) induces polyubiquitin protein accumulation and activates of the unfolded protein response (UPR) in AML cells[2].
CB-5339 (90 mg/kg for p.o.) decreases bone marrow leukemic infiltration and prolongs mice survival in MLL-AF9-driven patient-derived xenograft (PDX) AML mouse model[2].
| Catalog Number | I044331 |
| CAS Number | 1863952-15-1 |
| Synonyms | 1-[4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl]-2-methylindole-4-carboxamide |
| Molecular Formula | C24H24N6O |
| Purity | ≥95% |
| InChI | InChI=1S/C24H24N6O/c1-15-13-19-17(21(25)31)9-5-11-20(19)30(15)24-28-22-18(10-6-12-26-22)23(29-24)27-14-16-7-3-2-4-8-16/h2-5,7-9,11,13H,6,10,12,14H2,1H3,(H2,25,31)(H2,26,27,28,29) |
| InChIKey | XDHFSLWWYBVSLN-UHFFFAOYSA-N |
| SMILES | CC1=CC2=C(C=CC=C2N1C3=NC4=C(CCCN4)C(=N3)NCC5=CC=CC=C5)C(=O)N |
| Reference | [1]. David Wustrow, et al. FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX. WO2015109285A1. [2]. Roux B, et.al. Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Sci Transl Med. 2021 Mar 31;13(587):eabg1168. |
